DK0670735T3 - Perifisering af hæmotopoietiske stamceller. - Google Patents

Perifisering af hæmotopoietiske stamceller.

Info

Publication number
DK0670735T3
DK0670735T3 DK94903264.3T DK94903264T DK0670735T3 DK 0670735 T3 DK0670735 T3 DK 0670735T3 DK 94903264 T DK94903264 T DK 94903264T DK 0670735 T3 DK0670735 T3 DK 0670735T3
Authority
DK
Denmark
Prior art keywords
stem cells
hematopoietic stem
peripheral hematopoietic
peripheral
antibodies
Prior art date
Application number
DK94903264.3T
Other languages
Danish (da)
English (en)
Inventor
Thalia Papayannopoulou
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25525430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0670735(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of DK0670735T3 publication Critical patent/DK0670735T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94903264.3T 1992-11-13 1993-11-15 Perifisering af hæmotopoietiske stamceller. DK0670735T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97770292A 1992-11-13 1992-11-13
PCT/US1993/011060 WO1994011027A1 (fr) 1992-11-13 1993-11-15 Peripherisation de cellules souches hematopoietiques

Publications (1)

Publication Number Publication Date
DK0670735T3 true DK0670735T3 (da) 1997-07-28

Family

ID=25525430

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94903264.3T DK0670735T3 (da) 1992-11-13 1993-11-15 Perifisering af hæmotopoietiske stamceller.

Country Status (11)

Country Link
US (4) USRE40811E1 (fr)
EP (1) EP0670735B1 (fr)
JP (2) JP3731892B2 (fr)
AT (1) ATE150975T1 (fr)
AU (1) AU689454B2 (fr)
CA (1) CA2148712C (fr)
DE (1) DE69309487T2 (fr)
DK (1) DK0670735T3 (fr)
ES (1) ES2102196T3 (fr)
GR (1) GR3023975T3 (fr)
WO (1) WO1994011027A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670735B1 (fr) * 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripherisation de cellules souches hematopoietiques
EP0678122B1 (fr) * 1993-01-12 1999-07-28 Biogen, Inc. Molecules d'anticorps anti-vla4 de recombinaison
EP0682529B2 (fr) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Anticorps pour le traitement du diabete insulino-dependent
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
JP2002226377A (ja) * 1996-10-14 2002-08-14 Kirin Brewery Co Ltd 配糖体含有末梢血幹細胞増加剤
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
US20010038834A1 (en) * 1998-01-26 2001-11-08 Gary Balian Bone cancer therapy
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PL203114B1 (pl) 1998-09-14 2009-08-31 Regents Board Of Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1
US7838539B2 (en) * 1999-07-28 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
ATE325623T1 (de) * 1999-09-14 2006-06-15 Biogen Idec Inc Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
JP3459609B2 (ja) * 2000-03-17 2003-10-20 三洋電機株式会社 ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
US20040115175A1 (en) * 2000-11-10 2004-06-17 The Board Of Trustees Of The Leland Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
AU2002219830A1 (en) * 2000-11-10 2002-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US7994144B2 (en) * 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
AU2002318927B2 (en) 2001-07-31 2007-01-04 Genzyme Corporation Methods to mobilize progenitor/stem cells
CA2548580A1 (fr) * 2003-04-03 2004-10-21 Neostem, Inc. Prelevement et stockage facultatifs de cellules souches de sang peripherique autologues
US9403908B2 (en) 2003-09-29 2016-08-02 The Regents Of The University Of California Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
JP2007536935A (ja) 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 間葉幹細胞の無血清増殖のための細胞培養環境
EP1773981A1 (fr) * 2004-07-12 2007-04-18 Sorin Group Italia S.R.L. Dispositifs et procedes de culture de cellules humaines
CA2478458A1 (fr) * 2004-08-20 2006-02-20 Michael Panzara Traitement de la sclerose en plaques pediatrique
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
WO2010121141A1 (fr) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions et procédés pour traiter une leucémie myélogène aiguë
EP2550362B1 (fr) 2010-03-25 2017-01-04 Oregon Health&Science University Glycoprotéines du cmv et vecteurs recombinés
EP2558499B1 (fr) 2010-04-16 2017-04-12 Biogen MA Inc. Anticorps anti-vla-4
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (fr) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Protéines VLA
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
JPH07506091A (ja) 1992-01-13 1995-07-06 バイオゲン　インコーポレイテッド 喘息の処置
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE151642T1 (de) 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
EP0670735B1 (fr) * 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripherisation de cellules souches hematopoietiques
EP0682529B2 (fr) 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Anticorps pour le traitement du diabete insulino-dependent

Also Published As

Publication number Publication date
JP3731892B2 (ja) 2006-01-05
JPH08506091A (ja) 1996-07-02
AU5727294A (en) 1994-06-08
GR3023975T3 (en) 1997-10-31
EP0670735A1 (fr) 1995-09-13
JP2003277294A (ja) 2003-10-02
DE69309487T2 (de) 1997-10-23
EP0670735B1 (fr) 1997-04-02
US5843438A (en) 1998-12-01
WO1994011027A1 (fr) 1994-05-26
CA2148712C (fr) 2012-01-17
ES2102196T3 (es) 1997-07-16
US5824304A (en) 1998-10-20
US5695755A (en) 1997-12-09
ATE150975T1 (de) 1997-04-15
USRE40811E1 (en) 2009-06-30
AU689454B2 (en) 1998-04-02
CA2148712A1 (fr) 1994-05-26
DE69309487D1 (de) 1997-05-07

Similar Documents

Publication Publication Date Title
DK0670735T3 (da) Perifisering af hæmotopoietiske stamceller.
NO2014016I2 (no) Dimetylfumarat
ATE214943T1 (de) Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor
DE3686525D1 (de) Hochfeste einkristall-superlegierungszusammensetzungen.
DE69530763D1 (de) Antikörper gegen e-selektin
ES2122283T3 (es) Inhibicion del crecimiento capilar.
FI943728A0 (fi) Enkefalinaasin ja ACE:n inhibiittoreina käyttökelpoisia uusia aminoasetyylimerkaptojohdannaisia
IT7928417A0 (it) Composizioni farmaceutiche con esaltazione dell'attivita'terapeutica di cortisonici.
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
ES2173858T3 (es) Analogos de huperzina a.
PT734380E (pt) 4-benzoilisoxazois e sua utilizacao como herbicidas
NO941097D0 (no) Hudregenererende kosmetisk preparat
ES8607217A1 (es) Un procedimiento para la preparacion de (r)-4-amino-n-(1-fe-niletil)benzamida,(s)-4-amino-n-(1-feniletil)benzamida,o unasal de las mismas
BE1003463A4 (fr) Tensioactifs amphoteres contenant un oxyde d'alkylene.
IT1251961B (it) Peptidi che rappresentano permutazioni della sequenza del mastoparano
IT8324146A0 (it) Scorrevole in due parti per ancorare parti di protesi dentarie.
IT8412633A0 (it) Cinturino per orologio da polso formato da parti suddivisorie riunite presentabili frontalmente in alternativa di faccia
ITTO920109A0 (it) Per la migliore comprensione dell'invenzione e' stato necessario depositare disegni con diciture come consentito dalla convenzione europea sulle formalita' alla quale l'italia ha aderito
ATE269095T1 (de) Verfahren zur herstellung antitumoraler th1- zellen
IT1154760B (it) Cinturino smontabile inserito ad incastro nella cassa dell'crologio
CO4770982A1 (es) Nuevas formulaciones